121 related articles for article (PubMed ID: 38333962)
1. The Effectiveness of Adjuvant PD-1 Inhibitors in Patients With Surgically Resected Stage III/IV Acral Melanoma.
Arak H; Erkiliç S; Yaslikaya Ş; Eylemer Mocan E; Aktaş G; Özdemir M; Semiz HS; Kiliçkap S; Özalp FR; Sever ÖN; Akdağ G; Ağaoğlu AB; Özçelik M; Sari M; Arcagök M; Anik H; Yayla ŞB; Sever N; Açar FP; Bayrakçi İ; Turhal S; Ayhan M; Kuş T;
J Immunother; 2024 Jun; 47(5):182-189. PubMed ID: 38333962
[TBL] [Abstract][Full Text] [Related]
2. Low skeletal muscle mass predicts melanoma-specific survival in melanoma patients treated with adjuvant immune checkpoint blockade.
Mengoni M; Braun AD; Hinnerichs MS; Aghayev A; Tüting T; Surov A
J Cancer Res Clin Oncol; 2024 May; 150(5):275. PubMed ID: 38796605
[TBL] [Abstract][Full Text] [Related]
3. Real-world outcomes using PD-1 antibodies and BRAF + MEK inhibitors for adjuvant melanoma treatment from 39 skin cancer centers in Germany, Austria and Switzerland.
Schumann K; Mauch C; Klespe KC; Loquai C; Nikfarjam U; Schlaak M; Akçetin L; Kölblinger P; Hoellwerth M; Meissner M; Mengi G; Braun AD; Mengoni M; Dummer R; Mangana J; Sindrilaru MA; Radmann D; Hafner C; Freund J; Rappersberger K; Weihsengruber F; Meiss F; Reinhardt L; Meier F; Rainer B; Richtig E; Ressler JM; Höller C; Eigentler T; Amaral T; Peitsch WK; Hillen U; Harth W; Ziller F; Schatton K; Gambichler T; Susok L; Maul LV; Läubli H; Debus D; Weishaupt C; Börger S; Sievers K; Haferkamp S; Zenderowski V; Nguyen VA; Wanner M; Gutzmer R; Terheyden P; Kähler K; Emmert S; Thiem A; Sachse M; Gercken-Riedel S; Kaune KM; Thoms KM; Heinzerling L; Heppt MV; Tratzmiller S; Hoetzenecker W; Öllinger A; Steiner A; Peinhaupt T; Podda M; Schmid S; Wollina U; Biedermann T; Posch C
J Eur Acad Dermatol Venereol; 2023 May; 37(5):894-906. PubMed ID: 36433688
[TBL] [Abstract][Full Text] [Related]
4. Adjuvant Anti-PD-1 Immunotherapy versus Conventional Therapy for Stage III Melanoma: A Real-World Retrospective Cohort Study.
Li T; Xu Y; Sun W; Yan W; Wang C; Hu T; Zhang X; Luo Z; Liu X; Chen Y
Pharmaceuticals (Basel); 2022 Dec; 16(1):. PubMed ID: 36678538
[TBL] [Abstract][Full Text] [Related]
5. Comparative analysis of adjuvant therapy for stage III BRAF-mut melanoma: A real-world retrospective study from single center in China.
Zhong J; Sun W; Hu T; Wang C; Yan W; Luo Z; Liu X; Xu Y; Chen Y
Cancer Med; 2023 May; 12(10):11475-11482. PubMed ID: 37016119
[TBL] [Abstract][Full Text] [Related]
6. A real-world study of adjuvant anti-PD -1 immunotherapy on stage III melanoma with BRAF, NRAS, and KIT mutations.
Sun W; Xu Y; Yan W; Wang C; Hu T; Luo Z; Zhang X; Liu X; Chen Y
Cancer Med; 2023 Aug; 12(15):15945-15954. PubMed ID: 37403699
[TBL] [Abstract][Full Text] [Related]
7. Outcomes of patients with resected stage III/IV acral or mucosal melanoma, treated with adjuvant anti-PD-1 based therapy.
Jacques SK; McKeown J; Grover P; Johnson DB; Zaremba A; Dimitriou F; Weiser R; Farid M; Namikawa K; Sullivan RJ; Rutkowski P; Lebbe C; Hamid O; Zager JS; Michielin O; Neyns B; Nakamura Y; Robert C; Mehnert J; Ascierto PA; Bhave P; Park B; Zimmer L; Mangana J; Mooradian M; Placzke J; Allayous C; Glitza Oliva IC; Mehmi I; Depalo D; Wicky A; Schwarze JK; Roy S; Boatwright C; Vanella V; Long GV; Menzies AM; Lo SN; Carlino MS
Eur J Cancer; 2024 Mar; 199():113563. PubMed ID: 38278007
[TBL] [Abstract][Full Text] [Related]
8. Adjuvant immunotherapy for melanoma patients: progress and opportunities.
Sussman TA; Ott PA
ESMO Open; 2024 May; 9(5):102962. PubMed ID: 38626633
[TBL] [Abstract][Full Text] [Related]
9. [Efficacy of adjuvant programmed cell death 1 (PD-1) monoclonal antibody immunotherapy in Chinese patients with resected stage Ⅱ-Ⅲ melanoma].
Ren ZG; Xu Y; Hua ZZ; Mo ZY; Wang LW; Shi GB; Liu WL; Sun W; Zheng BQ; Wang CM; Jin YJ; Chen Y
Zhonghua Zhong Liu Za Zhi; 2023 Nov; 45(11):973-980. PubMed ID: 37968084
[No Abstract] [Full Text] [Related]
10. [Analysis of treatment and prognosis of 59 cases of vulvar melanoma].
Yuan GW; Li XG; Li N; Yao HW; Wu LY
Zhonghua Fu Chan Ke Za Zhi; 2020 Jun; 55(6):395-401. PubMed ID: 32842246
[No Abstract] [Full Text] [Related]
11. Adjuvant PD-1 inhibitor versus high-dose interferon α-2b for Chinese patients with cutaneous and acral melanoma: A retrospective cohort analysis.
Li J; Wang J; Li D; Wen X; Ding Y; Liu X; Jiang H; Huang F; Zhang X
Dermatol Ther; 2021 Sep; 34(5):e15067. PubMed ID: 34302318
[TBL] [Abstract][Full Text] [Related]
12. Treatment management for
Haist M; Stege H; Rogall F; Tan Y; von Wasielewski I; Klespe KC; Meier F; Mohr P; Kähler KC; Weichenthal M; Hauschild A; Schadendorf D; Ugurel S; Lodde G; Zimmer L; Gutzmer R; Debus D; Schilling B; Kreuter A; Ulrich J; Meiss F; Herbst R; Forschner A; Leiter U; Pfoehler C; Kaatz M; Ziller F; Hassel JC; Tronnier M; Sachse M; Dippel E; Terheyden P; Berking C; Heppt MV; Kiecker F; Haferkamp S; Gebhardt C; Simon JC; Grabbe S; Loquai C
J Immunother Cancer; 2023 Sep; 11(9):. PubMed ID: 37730278
[TBL] [Abstract][Full Text] [Related]
13. Prognostic impact of baseline tumour immune infiltrate on disease-free survival in patients with completely resected, BRAF
Ascierto PA; Lewis KD; Di Giacomo AM; Demidov L; Mandalà M; Bondarenko I; Herbert C; Mackiewicz A; Rutkowski P; Guminski A; Simmons B; Ye C; Hooper G; Wongchenko MJ; Goodman GR; Yan Y; Schadendorf D
Ann Oncol; 2020 Jan; 31(1):153-159. PubMed ID: 31912791
[TBL] [Abstract][Full Text] [Related]
14. Adjuvant pembrolizumab versus high-dose interferon α-2b for Chinese patients with resected stage III melanoma: a retrospective cohort study.
Li T; Jia DD; Teng LS
Invest New Drugs; 2020 Oct; 38(5):1334-1341. PubMed ID: 32072356
[TBL] [Abstract][Full Text] [Related]
15. Association of NRAS mutations and tertiary lymphoid structure formation with clinical outcomes of adjuvant PD-1 inhibitors for acral melanoma.
Mo Z; Liu J; Zhang J; Deng Y; Xu M; Jiang Y
Int Immunopharmacol; 2023 Nov; 124(Pt B):110973. PubMed ID: 37769536
[TBL] [Abstract][Full Text] [Related]
16. The prognostic significance of non-sentinel lymph node metastasis in cutaneous and acral melanoma patients-A multicenter retrospective study.
Sun W; Xu Y; Yang J; Liao Z; Li T; Huang K; Patel P; Yan W; Chen Y
Cancer Commun (Lond); 2020 Nov; 40(11):586-597. PubMed ID: 33025763
[TBL] [Abstract][Full Text] [Related]
17. Dabrafenib plus trametinib versus anti-PD-1 monotherapy as adjuvant therapy in
Bai X; Shaheen A; Grieco C; d'Arienzo PD; Mina F; Czapla JA; Lawless AR; Bongiovanni E; Santaniello U; Zappi H; Dulak D; Williamson A; Lee R; Gupta A; Li C; Si L; Ubaldi M; Yamazaki N; Ogata D; Johnson R; Park BC; Jung S; Madonna G; Hochherz J; Umeda Y; Nakamura Y; Gebhardt C; Festino L; Capone M; Ascierto PA; Johnson DB; Lo SN; Long GV; Menzies AM; Namikawa K; Mandala M; Guo J; Lorigan P; Najjar YG; Haydon A; Quaglino P; Boland GM; Sullivan RJ; Furness AJS; Plummer R; Flaherty KT
EClinicalMedicine; 2023 Nov; 65():102290. PubMed ID: 37965433
[TBL] [Abstract][Full Text] [Related]
18. Traditional risk factors and nodal yield-still relevant with high-quality risk-adapted adjuvant treatment for locally advanced head and neck cancer?
Butt Y; Tennstedt P; Busch CJ; Hanken H; Krüll A; Petersen C; Tribius S
Strahlenther Onkol; 2023 Mar; 199(3):284-292. PubMed ID: 36350358
[TBL] [Abstract][Full Text] [Related]
19. Adjuvant Systemic Therapies for Resected Stages III and IV Melanoma: A Multi-Center Retrospective Clinical Study.
Rigo R; Ding PQ; Batuyong E; Cheung WY; Walker J; Monzon JG; Cheng T
Oncologist; 2024 Jan; 29(1):57-66. PubMed ID: 37648247
[TBL] [Abstract][Full Text] [Related]
20. Adjuvant Therapy Failure Patterns in the Modern Era of Melanoma Management.
Rauwerdink DJW; Molina G; Frederick DT; Sharova T; Carmichael H; Boland GM
Ann Surg Oncol; 2020 Dec; 27(13):5128-5136. PubMed ID: 32447656
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
